FC084CSA
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for FC084CSA, covering 2025-08-07 to 2026-03-10. Get the full timeline:
Most recent: Clinical Trial Update: A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors [Phase 1, Phase 2]